Overall, while strong mechanistic and preliminary clinical evidence supports further investigation of anti-inflammatory therapies in aortic stenosis, ongoing clinical trials are limited to colchicine, despite genetic data suggesting a potential benefit of IL-6 inhibition with agents such as tocilizumab. This evidence concerns the gene IL6 and aortic stenosis.